| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.043 | 0.8 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.052 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |